Breaking News Instant updates and real-time market news.

TWTR

Twitter

, SBUX

Starbucks

$53.94

-0.14 (-0.26%)

09:18
08/25/17
08/25
09:18
08/25/17
09:18

On The Fly: Pre-market Movers

UP AFTER EARNINGS: Splunk (SPLK), up 10%. ALSO HIGHER: Adamas Pharmaceuticals (ADMS), up 43% after the FDA approved Gocovri extended release capsules for treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy... Kamada (KMDA), up 11% after KEDRAB received U.S. FDA approval for passive, transient post-exposure prophylaxis of rabies infection... Pure Storage (PSTG), up 7% after reporting earnings and naming former Cisco (CSCO) executive Charles Giancarlo as its new CEO... Starbucks (SBUX), up 1% after Wedbush analyst Nick Setyan upgraded the stock to Outperform from Neutral. DOWN AFTER EARNINGS: GameStop (GME), down 9%... Veeva (VEEV), down 9%... Ulta Beauty (ULTA), down 7%. ALSO LOWER: Twitter (TWTR), down 1% after Jefferies analyst Brent Thill downgraded the stock to Hold from Buy, stating that he prefers Google (GOOGL), Facebook (FB) and Snap (SNAP) as plays on the digital video transition occurring across the social media space.

TWTR

Twitter

SBUX

Starbucks

$53.94

-0.14 (-0.26%)

SPLK

Splunk

$60.28

-0.05 (-0.08%)

PSTG

Pure Storage

ADMS

Adamas Pharmaceuticals

$14.23

-0.16 (-1.11%)

KMDA

Kamada

$4.30

-0.15 (-3.37%)

GOOG

Alphabet

$921.28

-5.72 (-0.62%)

GOOGL

Alphabet Class A

$936.89

-5.69 (-0.60%)

FB

Facebook

$167.74

-0.97 (-0.57%)

SNAP

Snap

  • 29

    Aug

  • 12

    Sep

  • 13

    Sep

  • 02

    Nov

  • 25

    Jan

TWTR Twitter

08/25/17
JEFF
08/25/17
DOWNGRADE
Target $16
JEFF
Hold
Jefferies cuts Twitter with Google, Facebook and Snap preferred in social video
As previously reported, Jefferies analyst Brent Thill downgraded Twitter (TWTR) to Hold from Buy in a note to investors after the market close yesterday, stating that he prefers Google (GOOGL), Facebook (FB) and Snap (SNAP) as plays on the digital video transition occurring across the social media space. Thill, who thinks Twitter will underperform broader internet and social peers, acknowledged that investors might ask why he is not advising to sell the stock, but he thinks recent management changes could improve the company's declining ARPU in the near-term. Thill lowered his price target on Twitter shares to $16 from $20.
08/24/17
JEFF
08/24/17
DOWNGRADE
JEFF
Hold
Twitter downgraded to Hold from Buy at Jefferies
Jefferies analyst Brent Thill downgraded Twitter to Hold from Buy and lowered his price target to $16 from $20, citing diminishing return on investment for advertisers and a material deceleration of user growth.
08/24/17
JEFF
08/24/17
DOWNGRADE
JEFF
Hold
Twitter downgraded to Hold from Buy at Jefferies
08/16/17
08/16/17
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL), GoDaddy (GDDY), Wix.com (WIX), Alibaba (BABA), Amazon.com (AMZN), and Priceline (PCLN) were initiated with a Buy at SunTrust, while Snap (SNAP) was initiated with a Sell, and Twitter (TWTR) and eBay (EBAY) were initiated with a Hold. 2. HD Supply (HDS) reinstated with a Neutral at Goldman Sachs. 3. Shiloh Industries (SHLO) initiated with an Outperform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
SBUX Starbucks
$53.94

-0.14 (-0.26%)

08/21/17
STFL
08/21/17
NO CHANGE
STFL
Starbucks loyalty membership rate still declining, says Stifel
Stifel analyst Mark S. Astrachan says that 19% of respondents to a survey conducted by the firm say they are Starbucks loyalty members, three points below the six month average. He says that this metric is " generally viewed as a leading indicator of comparable store sales growth."
08/22/17
MSCO
08/22/17
NO CHANGE
Target $62
MSCO
Overweight
Market has adjusted to Starbucks moderating growth, says Morgan Stanley
Morgan Stanley analyst John Glass said the market has "quietly" adjusted to a more moderate long-term growth rate for Starbucks of 12%-17%. The analyst expects shares to hold its current valuation of 23x given a near best-in-class 25%+ ROIC, and sees upside once earnings visibility is reestablished. Glass maintains an Overweight rating on Starbucks and trimmed his price target to $62 from $68.
08/23/17
CLVD
08/23/17
DOWNGRADE
CLVD
Starbucks downgraded to Neutral from Buy at Cleveland Research
Cleveland Research downgraded Starbucks to Neutral saying there is less opportunity for comp upside and expects trends to be more in line with consensus estimates over the next 6 months. The firm's analyst said the America's comp estimate seems less clear over the near/medium term given increasing competition.
08/25/17
WEDB
08/25/17
UPGRADE
WEDB
Outperform
Starbucks upgraded to Outperform from Neutral at Wedbush
Wedbush analyst Nick Setyan upgraded Starbucks to Outperform from Neutral telling investors he expects shares to move higher following an expected revision in long-term growth targets in October and an update on the China joint-venture acquisition. Setyan said recent checks indicate U.S. comps are tracking in line with Q4 consensus of 3.5% and thinks a 4% comp is realistic if trends continue through September. After the Q3 report, FY18 consensus U.S. comps declined to 3.9% from 4.7%, and the analyst believes this decline anticipates management lowering long-term mid-single digit same-store-sales growth target to a range of 3-5% in October, which should remove a valuation headwind. Additionally, Setyan said commentary indicates the China joint-venture will add 100 bps of incremental FY18 revenue growth and estimates an incremental 1-2% of earnings growth beginning in FY19. The analyst raised Starbucks price target to $60 from $57 in conjunction with the upgrade.
SPLK Splunk
$60.28

-0.05 (-0.08%)

08/25/17
UBSW
08/25/17
NO CHANGE
Target $74
UBSW
Buy
Splunk results show execution remains on track, says UBS
UBS analyst Fatima Boolani noted Splunk reported solid Q2 earnings following its Q1 trough and said its results show its execution appears back on track. The analyst said she remains positive on the longer-term opportunities for continued growth for Splunk, citing its big addressable market, strong tech sector, steady execution and limited competitive threats. Boolani reiterated her Buy rating and raised her price target to $74 from $72 on Splunk shares.
08/25/17
MUFG
08/25/17
NO CHANGE
Target $75
MUFG
Overweight
Splunk price target raised to $75 from $71 at MUFG
MUFG analyst Stephen Bersey believes Splunk's end markets are still in the early stages of growth and noted that the 32% year-over-year top line growth it reported in Q2 puts it in the top quartile for revenue growth among the software names the firm covers. Following what he called a "strong" quarter, he reiterated his Overweight rating and raised his price target on Splunk to $75 from $71.
08/25/17
ADAM
08/25/17
NO CHANGE
Target $80
ADAM
Buy
Splunk price target raised to $80 from $75 at Canaccord
Canaccord analyst Richard Davis raised his price target on Splunk to $80 from $75 following solid Q2 results. The analyst said the company has executed well, has built a valuable franchise and remains undervalued. Davis believes the company is well positioned and statistically inexpensive and reiterated his Buy rating on Splunk shares.
08/25/17
SUSQ
08/25/17
UPGRADE
Target $76
SUSQ
Positive
Splunk upgraded to Positive at Susquehanna
As reported previously, Susquehanna analyst Anne Meisner upgraded Splunk to Positive from Neutral. The analyst said its solid results demonstrated an impressive reacceleration in license revenue and a significant improvement in EMEA performance, giving her confidence last quarter's deceleration was execution related rather than indicative of a more permanent slowdown. Meisner raised her price target to $76 from $68 on Splunk shares.
PSTG Pure Storage

08/14/17
MAXM
08/14/17
DOWNGRADE
Target $15
MAXM
Hold
Pure Storage downgraded to Hold from Buy at Maxim
Maxim analyst Nehal Chokshi downgraded Pure Storage (PSTG) to Hold and cut his price target for the shares to $15 from $20. The analyst believes Flash Blade's "lack of depth of data management features" presents risk to meeting guidance of accelerating year-over-year growth. The analyst this morning also upgraded NetApp (NTAP) to Buy.
08/14/17
08/14/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Babcock & Wilcox (BW) downgraded to Neutral from Buy at UBS with analyst Steven Fisher citing lower earnings, ongoing project issues and more debt on the balance sheet following the company's second quarter results. The analyst cut his price target for the shares to $3 from $13. 2. Summit Hotel Properties (INN) downgraded to Underperform from Buy at BofA/Merrill. 3. Pure Storage (PSTG) downgraded to Hold from Buy at Maxim with analyst Nehal Chokshi saying he believes Flash Blade's "lack of depth of data management features" presents risk to meeting guidance of accelerating year-over-year growth. 4. CNO Financial (CNO) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Nigel Dally saying valuation is full with shares near all-time highs and has concerns about deteriorating sales and management's tempered expectations around ROE growth. 5. Acushnet Holdings (GOLF) downgraded on growth concerns at DA Davidson with analyst Andrew Bruns citing his increased caution on the growth outlook of its Club, FootJoy and Performance units. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/25/17
UBSW
08/25/17
NO CHANGE
Target $15
UBSW
Buy
Pure Storage risk/reward favorable, says UBS
UBS analyst Steven Milunovich said the risk/reward for Pure Storage remains favorable following its moderate Q2 earnings beat. The analyst also noted the company's announcement of a CEO change during a strong quarter was a surprise, but a good move. He said he remains bullish as Pure Storage is about to cross over into positive free cash flow territory and should turn a profit in Q4. Milunovich reiterated his Buy rating and $15 price target on Pure Storage shares.
08/25/17
SMTR
08/25/17
UPGRADE
SMTR
Buy
Pure Storage upgraded to Buy from Hold at Summit Redstone
ADMS Adamas Pharmaceuticals
$14.23

-0.16 (-1.11%)

08/09/17
COWN
08/09/17
NO CHANGE
Target $45
COWN
Outperform
Adamas Pharmaceuticals nearing valuation inflection, says Cowen
Cowen analyst Ken Cacciatore believes Adamas Pharmaceuticals' Parkinson's drug will be approved by late August as it is differentiated and addresses an unmet need. The analyst feels it should be a significant near term value creator and recommends investors add to positions. Cacciatore reiterated his Outperform rating and $45 price target on Adamas Pharmaceuticals shares.
08/17/17
JMPS
08/17/17
NO CHANGE
JMPS
Adamas Pharmaceuticals shares should be bought on weakness, says JMP Securities
JMP Securities analyst Jason Butler says that Adamas Pharmaceuticals shares should be bought on weakness ahead of the August 24 PDUFA date for its ADS-5102 drug. The analyst thinks that the weakness in the stock has been driven primarily by risk disclosures it made related to the approvability and product label of the drug. However, the analyst says that the warnings are "benign" and have no impact on the drug's approvability. He continues to believe that investors are underestimating the drug's outlook and keeps a $29 price target and an Outperform rating on the stock.
08/25/17
COWN
08/25/17
NO CHANGE
Target $55
COWN
Outperform
Adamas Pharmaceuticals price target raised to $55 from $45 at Cowen
Cowen analyst Ken Cacciatore raised his price target on Adamas Pharmaceuticals to $55 from $45 after the company received approval of its Parkinson's treatment expected to launch in 2018. He noted consultants have been consistent in their belief the drug is differentiated, addresses an unmet need, and will be a welcome addition to the Parkinson's treatment paradigm. Cacciatore reiterated his Outperform rating on Adamas shares.
08/25/17
JMPS
08/25/17
NO CHANGE
JMPS
Adamas Pharmaceuticals price target raised to $33 from $29 at JMP Securities
JMP Securities analyst Jason Butler raised his price target on Adamas after the FDA approved its GOCOVRI drug as an adjunctive treatment for Parkinson's disease patients. The analyst says that the drug's label is "broad." He keeps an Outperform rating on the stock.
KMDA Kamada
$4.30

-0.15 (-3.37%)

GOOG Alphabet
$921.28

-5.72 (-0.62%)

08/17/17
RBCM
08/17/17
NO CHANGE
RBCM
Broadcom results, guidance poised to beat expectations, says RBC Capital
RBC Capital analyst Amit Daryanani says that Broadcom (AVGO) "is positioned" to report better than expected results for its July quarter and provide better than expected guidance for its October quarter, " driven by positive catalysts that are boosting its wireless and wired businesses. Among the company's near-term positive catalysts are the iPhone ramp and "custom ASIC ramps with Google (GOOG,GOOGL) and others," according to Daryanani. He keeps a $270 price target and a Top Pick rating on Broadcom.
08/22/17
FBCO
08/22/17
NO CHANGE
FBCO
Facebook at top of investors preferences in consumer internet sector, says Credit Suisse
According to conversations he had over the last few weeks, Credit Suisse analyst Stephen Ju says not much has changed in positioning around long-term investment theses, with earnings results driving the willingness to upside/downsize. Hence investors' most favored list has shifted to number 1 Facebook (FB), number 2 Amazon (AMZN), and number 3 Google (GOOG; GOOGL), he said. Away from the large caps, the analyst notes that MercadoLibre (MELI) as well as the videogame stocks remain popular topics for discussion, with increasing activity in Take-Two (TTWO) relative to Activision Blizzard (ATVI) and Electronic Arts (EA).
08/24/17
BARD
08/24/17
NO CHANGE
Target $85
BARD
Outperform
Wal-Mart partnership with Google a 'thoughtful, strategic' move, says Baird
Baird analyst Peter Benedict called the voice-based shopping partnership between Wal-Mart (WMT) and Google (GOOG) both thoughtful and strategic. He believes its demonstrates the value of Wal-Mart's national footprint and its emerging leadership role in the digital commerce world. Benedict reiterated his Outperform rating and $85 price target on Wal-Mart shares.
GOOGL Alphabet Class A
$936.89

-5.69 (-0.60%)

08/23/17
KEYB
08/23/17
NO CHANGE
KEYB
Wal-Mart, Alphabet deal to increase competition for Amazon, says KeyBanc
KeyBanc says that the partnership deal announced today between Wal-Mart (WMT) and Alphabet (GOOG,GOOGL) will intensify the competition facing Amazon (AMZN). The firm says that the deal will give consumers the capacity to obtain Wal-Mart products through voice ordering. Voice ordering had previously been a competitive advantage of Amazon, according to the firm ,which adds that Wal-Mart's acquisitions and investments have improved its e-commerce offerings.
FB Facebook
$167.74

-0.97 (-0.57%)

08/23/17
CANT
08/23/17
NO CHANGE
CANT
Snap gaining share among teens/young adults, says Cantor
According to Cantor analyst Kip Paulson, eMarketer's forecast shows that Snap's share of U.S. social network users has reached 40.8%, while its monthly users are expected to increase 25.8% this year. Paulson adds that the website is expected to overtake Facebook (FB) and Instagram among the 12-17 and 18-24 cohorts this year. He keeps a $15 price target and an Overweight rating on Snap.
08/17/17
AGIS
08/17/17
NO CHANGE
Target $15
AGIS
Hold
Aegis incrementally positive on Snap after management call
After speaking with Snap's (SNAP) Chief Strategy Officer Imran Khan and Chief Financial Officer Andrew Vollero, Aegis analyst Victor Anthony is incrementally positive on the company's longer-term outlook. The analyst raised his price target for the shares to $15 from $14 but keeps a Hold rating on the name. The analyst continues to see "near-term hurdles" as Snap tries to attract more advertisers, improve measurement and analytics, solve user growth issues on Android, and address competitive challenges from Facebook's (FB) Instagram.
SNAP Snap

TODAY'S FREE FLY STORIES

19:15
10/20/17
10/20
19:15
10/20/17
19:15
General news
Breaking General news story  »

Federal Reserve Chair…

ATRS

Antares Pharma

$2.18

0.06 (2.83%)

18:59
10/20/17
10/20
18:59
10/20/17
18:59
Hot Stocks
FDA cannot approve Antares Pharma's Xyosted NDA »

Antares Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

18:55
10/20/17
10/20
18:55
10/20/17
18:55
Conference/Events
Federal Reserve Chairperson delivers a lecture at NEC Dinner »

Federal Reserve…

SHIP

Seanergy Marine

$1.24

0.0199 (1.63%)

17:50
10/20/17
10/20
17:50
10/20/17
17:50
Syndicate
Breaking Syndicate news story on Seanergy Marine »

Seanergy Marine files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLI

Houlihan Lokey

$41.56

0.18 (0.43%)

17:49
10/20/17
10/20
17:49
10/20/17
17:49
Syndicate
Breaking Syndicate news story on Houlihan Lokey »

Houlihan Lokey files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GEO

Geo Group

$26.20

0.2 (0.77%)

17:48
10/20/17
10/20
17:48
10/20/17
17:48
Syndicate
Breaking Syndicate news story on Geo Group »

Geo Group files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

17:37
10/20/17
10/20
17:37
10/20/17
17:37
Hot Stocks
DBV sinks following peanut allergy trial miss, Aimmune soars »

Shares of DBV…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KALV

KalVista

$11.26

1.99 (21.47%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:24
10/20/17
10/20
17:24
10/20/17
17:24
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: KalVista (KALV),…

KALV

KalVista

$11.26

1.99 (21.47%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPCI

Intellipharmaceutics

17:23
10/20/17
10/20
17:23
10/20/17
17:23
Hot Stocks
Breaking Hot Stocks news story on Intellipharmaceutics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:21
10/20/17
10/20
17:21
10/20/17
17:21
Hot Stocks
DBV Technologies: PEPITES trial does not reach primary endpoint »

DBV Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.92

1.17 (2.18%)

17:08
10/20/17
10/20
17:08
10/20/17
17:08
Periodicals
Regulator criticizes Wells Fargo over deceptive auto insurance program, NYT says »

The Office of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

  • 07

    Nov

  • 29

    Nov

  • 15

    Jan

ALIM

Alimera Sciences

17:01
10/20/17
10/20
17:01
10/20/17
17:01
Syndicate
Alimera Sciences to sell $25M in shares in an 'at the market offering' »

On October 20, Alimera…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYMC

Symantec

$32.66

0.33 (1.02%)

16:51
10/20/17
10/20
16:51
10/20/17
16:51
Syndicate
Breaking Syndicate news story on Symantec »

Symantec files to sell 1M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

EBMT

Eagle Bancorp

$19.55

0.15 (0.77%)

16:44
10/20/17
10/20
16:44
10/20/17
16:44
Hot Stocks
Breaking Hot Stocks news story on Eagle Bancorp »

EJF Capital reports 7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALV

KalVista

$11.26

1.99 (21.47%)

16:43
10/20/17
10/20
16:43
10/20/17
16:43
Hot Stocks
Breaking Hot Stocks news story on KalVista »

Longwood Fund II reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAGX

Jaguar Health

$0.19

0.002 (1.08%)

16:41
10/20/17
10/20
16:41
10/20/17
16:41
Syndicate
Breaking Syndicate news story on Jaguar Health »

Jaguar Health files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$345.10

-6.71 (-1.91%)

16:40
10/20/17
10/20
16:40
10/20/17
16:40
Hot Stocks
Tesla amends 'warehouse agreements' to increase commitments to $1.1B »

On October 18,Tesla…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 06

    Nov

SNV

Synovus

$47.30

0.54 (1.15%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Hot Stocks
Synovus CBO sells 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

  • 15

    Nov

GTXI

GTx

$7.92

0.1 (1.28%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Syndicate
Breaking Syndicate news story on GTx »

GTx files to sell 8.77M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

, BKMU

BankMutual

$10.80

0.55 (5.37%)

16:36
10/20/17
10/20
16:36
10/20/17
16:36
Conference/Events
BankMutual to host special shareholder meeting »

Special Shareholder…

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

BKMU

BankMutual

$10.80

0.55 (5.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

CNXR

Connecture

$0.49

-0.01 (-2.00%)

16:35
10/20/17
10/20
16:35
10/20/17
16:35
Hot Stocks
Breaking Hot Stocks news story on Connecture »

Connecture trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$23.83

0.25 (1.06%)

, PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

16:31
10/20/17
10/20
16:31
10/20/17
16:31
General news
On The Fly: Top stock stories for Friday »

Stocks opened sharply…

GE

General Electric

$23.83

0.25 (1.06%)

PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

CELG

Celgene

$121.33

-14.63 (-10.76%)

SNCR

Synchronoss

$11.39

-0.12 (-1.04%)

IL

Bought by SNCR

SKX

Skechers

$33.99

9.96 (41.45%)

PYPL

PayPal

$70.97

3.72 (5.53%)

NCR

NCR Corp.

$33.05

-4 (-10.80%)

LHO

LaSalle Hotel

$28.52

-1.94 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

  • 08

    Nov

  • 29

    Nov

  • 30

    Nov

16:30
10/20/17
10/20
16:30
10/20/17
16:30
Options
Preliminary option volume of 22.9M today »

Preliminary option volume…

MKL

Markel

$1,078.23

14.88 (1.40%)

, SNC

State National

$21.05

0.02 (0.10%)

16:26
10/20/17
10/20
16:26
10/20/17
16:26
Conference/Events
State National to host special shareholder meeting »

Special Shareholder…

MKL

Markel

$1,078.23

14.88 (1.40%)

SNC

State National

$21.05

0.02 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

RYTM

Rhythm Pharmaceuticals

$23.08

-0.17 (-0.73%)

16:22
10/20/17
10/20
16:22
10/20/17
16:22
Hot Stocks
Breaking Hot Stocks news story on Rhythm Pharmaceuticals »

Orbimed Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.